ifosfamide has been researched along with Adenocarcinoma, Basal Cell in 157 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "There are currently no approved therapies for patients with metastatic pancreatic adenocarcinoma previously treated with gemcitabine." | 9.14 | A randomised Phase III trial of glufosfamide compared with best supportive care in metastatic pancreatic adenocarcinoma previously treated with gemcitabine. ( Bodoky, G; Ciuleanu, TE; Garin, AM; Kroll, S; Langmuir, VK; Pavlovsky, AV; Tidmarsh, GT, 2009) |
| "Fifty-two patients with advanced adenocarcinoma of the endometrium recurrent after surgery and/or radiation therapy and refractory to first-line chemotherapeutic agents were treated with ifosfamide, 1." | 9.07 | Phase II study of ifosfamide and mesna in refractory adenocarcinoma of the endometrium. A Gynecologic Oncology Group study. ( Adcock, L; Blessing, JA; Homesley, HD; McGuire, WP; Sutton, GP, 1994) |
| "A phase II trial of ifosfamide (IFX) and mesna was conducted by the GOG in patients with recurrent or advanced nonsquamous carcinoma of the cervix." | 9.07 | Phase II study of ifosfamide and mesna in nonsquamous carcinoma of the cervix: a Gynecologic Oncology Group study. ( Blessing, JA; DiSaia, PJ; McGuire, WP; Sutton, GP, 1993) |
| "We report the effectiveness of a combination chemotherapy consisting of ifosfamide, 5-fluorouracil, etoposide and cisplatin (IFEP chemotherapy) against metastatic adenocarcinoma of the urachus." | 7.74 | Preliminary report of multimodal treatment with ifosfamide, 5-fluorouracil, etoposide and cisplatin (IFEP chemotherapy) against metastatic adenocarcinoma of the urachus. ( Fujii, Y; Fukui, I; Ishikawa, Y; Kawakami, S; Komai, Y; Okubo, Y; Takeshita, H; Tatokoro, M; Yamamoto, S; Yonese, J, 2008) |
| "We report a patient with primary lung adenocarcinoma who had Ewing's sarcoma and was successfully treated with ifosfamide." | 7.74 | [A case of primary lung adenocarcinoma accompanied by Ewing's sarcoma successfully treated with ifosfamide]. ( Arai, H; Fukumura, H; Kudo, M; Masuda, M; Nakajima, K; Oshiro, H; Rino, Y; Wada, N; Watanuki, Y; Yamanaka, S; Yukawa, N, 2008) |
| "In advanced adenocarcinoma of the pancreas treatment with 5-fluorouracil (5-FU) or ifosfamide results in response rates of approximately 20%." | 7.69 | Intermittent continuous infusion of ifosfamide and 5-fluorouracil in patients with advanced adenocarcinoma of the pancreas. ( Bakker, PJ; Gouma, DJ; Huizing, MT; Poorter, RL; Rauws, EA; Rietbroek, RC; Taat, CW; Veenhof, CH, 1995) |
| " An extension of the comparative study to the in vivo model of murine C3H mammary adenocarcinoma yielded synergistic effects, if the animals were treated with 10 MeV electrons and one of the drugs: cis-platinum, adriamycin, epirubicin, activated cyclophosphamide, activated isophosphamide." | 7.68 | Biophysical aspects of the integrated combination of cytostatic drugs with radiotherapy. Part 3: In vivo investigations on murine C3H mammary adenocarcinoma treated with cis-platinum, adriamycin, epirubicin, activated cyclophosphamide, activated isophosph ( Ulmer, W, 1991) |
| "Forty seven patients with inoperable adenocarcinoma and large cell carcinoma of the lung were treated with a combination of cisplatin (25 mg/m2), ifosfamide (1." | 7.68 | [Clinical study of combination chemotherapy with cisplatin, ifosfamide, 5-FU (CIF therapy) of inoperable adenocarcinoma and large cell carcinoma of the lung]. ( Asakawa, M; Fujita, A; Honda, R; Inoue, Y; Mori, T; Nakajima, S; Sasaki, H; Sekine, K; Suzuki, A, 1991) |
| "25 previously untreated patients with inoperable or metastatic adenocarcinoma of the oesophagus or oesophageal-gastric junction area were treated with ifosfamide 6 g/m2 over 48 hours, combined with mesna 6 g/m2." | 7.68 | Ifosfamide in advanced adenocarcinoma of the oesophagus or oesophageal-gastric junction area. Rotterdam Esophageal Tumor Study Group. ( Kok, TC; Splinter, TA; Tilanus, HW; van der Gaast, A, 1991) |
| "Fourteen evaluable patients with gynecologic adenocarcinoma (7 ovarian, 4 endometrial, 2 peritoneal and one breast cancer) were treated with ifosfamide (1 g/m2 X 5 days), adriamycin (50 mg/m2) and cisplatin (50 mg/m2) combined chemotherapy (IAP)." | 7.67 | Treatment of gynecological adenocarcinomas with a combination of ifosfamide, adriamycin and cisplatin. ( Nagasue, N; Nishida, T, 1988) |
| "Nineteen patients with hormonal refractory adenocarcinoma of the prostate were treated with ifosfamide (IFM) and the combination of vincristine, ifosfamide and peplomycin (VIP)." | 7.67 | [Treatment of hormonal refractory adenocarcinoma of the prostate with ifosfamide (IFM) and the combination of vincristine ifosfamide and peplomycin (VIP)]. ( Ebisui, K; Fujiwara, M; Kobayashi, T; Miyakoda, K; Nakagawa, S; Nakao, M; Nukui, M; Takada, H; Toyoda, K; Watanabe, H, 1989) |
| "From April 1982, until February 1984, 29 patients with biopsy-proven and measurable adenocarcinoma of the pancreas were treated with ifosfamide." | 7.67 | Ifosfamide: an active drug in the treatment of adenocarcinoma of the pancreas. ( Ansari, R; Einhorn, LH; Loehrer, PJ; Williams, SD, 1985) |
| "Fifty-three patients with inoperable non-small cell bronchial carcinoma were treated at four-weekly intervals with two cytostatic drugs, doxorubicin (50 mg/m2 on day 1) and ifosfamide (2000 mg/m2 on days 1-3)." | 7.66 | [Combined cytostatic chemotherapy of advanced non-small-cell bronchial carcinoma with doxorubicin and ifosfamide]. ( Göbel, D; Matthiessen, W; Stempinski, E; Thalmann, U, 1983) |
| " Alternative dosing of glufosfamide plus gemcitabine should be explored." | 6.75 | A phase 2 trial of glufosfamide in combination with gemcitabine in chemotherapy-naive pancreatic adenocarcinoma. ( Barrios, CH; Chiorean, EG; Dragovich, T; Gorini, CF; Hamm, J; Jung, DT; Kroll, S; Langmuir, VK; Loehrer, PJ; Tidmarsh, GT, 2010) |
| "Phase I data indicate that full dose glufosfamide (4,500 mg/m(2)) can be given safely in combination with gemcitabine." | 6.73 | A Phase 1 dose-escalation trial of glufosfamide in combination with gemcitabine in solid tumors including pancreatic adenocarcinoma. ( Chiorean, EG; Colowick, AB; Dragovich, T; Hamm, J; Jung, DT; Kroll, S; Langmuir, VK; Loehrer, PJ; Tidmarsh, GF, 2008) |
| "Local control rate for inflammatory breast cancer (IBC) is < 50% with standard chemotherapy-radiotherapy regimen." | 5.30 | Inflammatory breast cancer: enhanced local control with hyperfractionated radiotherapy and infusional vincristine, ifosfamide and epirubicin. ( Boyages, J; Gurney, H; Harnett, P; Kefford, R, 1998) |
| "There are currently no approved therapies for patients with metastatic pancreatic adenocarcinoma previously treated with gemcitabine." | 5.14 | A randomised Phase III trial of glufosfamide compared with best supportive care in metastatic pancreatic adenocarcinoma previously treated with gemcitabine. ( Bodoky, G; Ciuleanu, TE; Garin, AM; Kroll, S; Langmuir, VK; Pavlovsky, AV; Tidmarsh, GT, 2009) |
| " Thirty patients with poorly-differentiated carcinoma or poorly-differentiated adenocarcinoma (group A) received a combination of cisplatin and etoposide." | 5.09 | Carcinoma of an unknown primary site: a chemotherapy strategy based on histological differentiation--results of a prospective study. ( Borel, C; Ducreux, M; Fizazi, K; Le Chevalier, T; Ruffié, P; Saghatchian, M; Théodore, C, 2001) |
| "Fifty-two patients with advanced adenocarcinoma of the endometrium recurrent after surgery and/or radiation therapy and refractory to first-line chemotherapeutic agents were treated with ifosfamide, 1." | 5.07 | Phase II study of ifosfamide and mesna in refractory adenocarcinoma of the endometrium. A Gynecologic Oncology Group study. ( Adcock, L; Blessing, JA; Homesley, HD; McGuire, WP; Sutton, GP, 1994) |
| "A phase II trial of ifosfamide (IFX) and mesna was conducted by the GOG in patients with recurrent or advanced nonsquamous carcinoma of the cervix." | 5.07 | Phase II study of ifosfamide and mesna in nonsquamous carcinoma of the cervix: a Gynecologic Oncology Group study. ( Blessing, JA; DiSaia, PJ; McGuire, WP; Sutton, GP, 1993) |
| "Herein we present a unique case report of a 47-year- old man with metastatic adenocarcinoma of rete testis who achieved substantial disease response after four cycles of paclitaxel, ifosfamide and cisplatin." | 3.80 | Adenocarcinoma of the rete testis - a rare case of testicular malignancy. ( Chovanec, M; Mardiak, J; Mego, M; Obertova, J; Palacka, P; Rajec, J; Sycova-Mila, Z, 2014) |
| "We report the effectiveness of a combination chemotherapy consisting of ifosfamide, 5-fluorouracil, etoposide and cisplatin (IFEP chemotherapy) against metastatic adenocarcinoma of the urachus." | 3.74 | Preliminary report of multimodal treatment with ifosfamide, 5-fluorouracil, etoposide and cisplatin (IFEP chemotherapy) against metastatic adenocarcinoma of the urachus. ( Fujii, Y; Fukui, I; Ishikawa, Y; Kawakami, S; Komai, Y; Okubo, Y; Takeshita, H; Tatokoro, M; Yamamoto, S; Yonese, J, 2008) |
| " Three courses with cisplatin 75 mg/m(2), paclitaxel 175 mg/m(2) and ifosfamide 5 g/m(2) (epirubicin 80 mg/m(2) in adenocarcinoma) were followed by cold-knife conization and pelvic lymphadenectomy." | 3.74 | Neoadjuvant chemotherapy and conservative surgery for stage IB1 cervical cancer. ( Bonazzi, C; Chiari, S; Maneo, A; Mangioni, C, 2008) |
| "We report a patient with primary lung adenocarcinoma who had Ewing's sarcoma and was successfully treated with ifosfamide." | 3.74 | [A case of primary lung adenocarcinoma accompanied by Ewing's sarcoma successfully treated with ifosfamide]. ( Arai, H; Fukumura, H; Kudo, M; Masuda, M; Nakajima, K; Oshiro, H; Rino, Y; Wada, N; Watanuki, Y; Yamanaka, S; Yukawa, N, 2008) |
| " We report a patient who was cured of metastatic adenocarcinoma in Barrett's oesophagus by six courses of ifosfamide, a chemotherapeutic agent with little or no activity in other patients with adenocarcinoma of the oesophagus or gastro-oesophageal junction." | 3.71 | Cure of Barrett's carcinoma by ifosfamide chemotherapy. ( Hage, M; Kok, TC; Kuipers, EJ; Siersema, PD; Tilanus, HW; van Dekken, H; van der Gaast, A, 2002) |
| "In advanced adenocarcinoma of the pancreas treatment with 5-fluorouracil (5-FU) or ifosfamide results in response rates of approximately 20%." | 3.69 | Intermittent continuous infusion of ifosfamide and 5-fluorouracil in patients with advanced adenocarcinoma of the pancreas. ( Bakker, PJ; Gouma, DJ; Huizing, MT; Poorter, RL; Rauws, EA; Rietbroek, RC; Taat, CW; Veenhof, CH, 1995) |
| "The multidrug resistance gene product P-glycoprotein (P-GP) was assessed immunohistochemically (by antibody JSB-1) in biopsy specimens from 27 oesophageal squamous carcinomas and 10 adenocarcinomas before treatment with mitomycin, ifosfamide and cisplatin (MIC)." | 3.69 | Lack of correlation of P-glycoprotein expression with response to MIC chemotherapy in oesophageal cancer. ( Darnton, SJ; Ferry, DR; Jenner, K; Matthews, HR; Steyn, RS, 1995) |
| "Patients with advanced adenocarcinoma of the lung with measurable or assessable disease received chemotherapy with mesna, ifosfamide, carboplatin, and etoposide (MICE)." | 3.69 | Mutational activation of the K-ras oncogene and the effect of chemotherapy in advanced adenocarcinoma of the lung: a prospective study. ( Boerrigter, L; Mooi, WJ; Rodenhuis, S; Slebos, RJ; Top, B; van Zandwijk, N; van't Veer, L, 1997) |
| " An extension of the comparative study to the in vivo model of murine C3H mammary adenocarcinoma yielded synergistic effects, if the animals were treated with 10 MeV electrons and one of the drugs: cis-platinum, adriamycin, epirubicin, activated cyclophosphamide, activated isophosphamide." | 3.68 | Biophysical aspects of the integrated combination of cytostatic drugs with radiotherapy. Part 3: In vivo investigations on murine C3H mammary adenocarcinoma treated with cis-platinum, adriamycin, epirubicin, activated cyclophosphamide, activated isophosph ( Ulmer, W, 1991) |
| "Forty seven patients with inoperable adenocarcinoma and large cell carcinoma of the lung were treated with a combination of cisplatin (25 mg/m2), ifosfamide (1." | 3.68 | [Clinical study of combination chemotherapy with cisplatin, ifosfamide, 5-FU (CIF therapy) of inoperable adenocarcinoma and large cell carcinoma of the lung]. ( Asakawa, M; Fujita, A; Honda, R; Inoue, Y; Mori, T; Nakajima, S; Sasaki, H; Sekine, K; Suzuki, A, 1991) |
| "Of 13 patients with adenocarcinoma treated with 5-fluorouracil, adriamycin, and mitomycin (FAM), nine showed minor histological changes compared with 14 control cases." | 3.68 | Histopathological findings in oesophageal carcinoma with and without preoperative chemotherapy. ( Allen, SM; Darnton, SJ; Edwards, CW; Matthews, HR, 1993) |
| "Ten resected oesophageal adenocarcinomas treated with preoperative chemotherapy--mitomycin-C, ifosfamide, and cisplatin (MIC)--were examined by transmission electron microscopy and their appearance compared with that of 13 concurrent untreated resected oesophageal adenocarcinomas." | 3.68 | Effects of chemotherapy on ultrastructure of oesophageal adenocarcinoma. ( Antonakopoulos, GN; Darnton, SJ; Matthews, HR; Newman, J, 1992) |
| "25 previously untreated patients with inoperable or metastatic adenocarcinoma of the oesophagus or oesophageal-gastric junction area were treated with ifosfamide 6 g/m2 over 48 hours, combined with mesna 6 g/m2." | 3.68 | Ifosfamide in advanced adenocarcinoma of the oesophagus or oesophageal-gastric junction area. Rotterdam Esophageal Tumor Study Group. ( Kok, TC; Splinter, TA; Tilanus, HW; van der Gaast, A, 1991) |
| "From April 1982, until February 1984, 29 patients with biopsy-proven and measurable adenocarcinoma of the pancreas were treated with ifosfamide." | 3.67 | Ifosfamide: an active drug in the treatment of adenocarcinoma of the pancreas. ( Ansari, R; Einhorn, LH; Loehrer, PJ; Williams, SD, 1985) |
| "Twelve patients with stage D2 adenocarcinoma of the prostate were treated with the combination chemotherapy of ifosfamide (2 g/body, i." | 3.67 | [Combination chemotherapy with ifosfamide, 5-fluorouracil, cisplatin for stage D2 prostatic cancer]. ( Andoh, M; Fukui, I; Higashi, Y; Horiuchi, S; Kihara, K; Kitahara, S; Oshima, H; Takeuchi, S, 1989) |
| "Fourteen evaluable patients with gynecologic adenocarcinoma (7 ovarian, 4 endometrial, 2 peritoneal and one breast cancer) were treated with ifosfamide (1 g/m2 X 5 days), adriamycin (50 mg/m2) and cisplatin (50 mg/m2) combined chemotherapy (IAP)." | 3.67 | Treatment of gynecological adenocarcinomas with a combination of ifosfamide, adriamycin and cisplatin. ( Nagasue, N; Nishida, T, 1988) |
| "Nineteen patients with hormonal refractory adenocarcinoma of the prostate were treated with ifosfamide (IFM) and the combination of vincristine, ifosfamide and peplomycin (VIP)." | 3.67 | [Treatment of hormonal refractory adenocarcinoma of the prostate with ifosfamide (IFM) and the combination of vincristine ifosfamide and peplomycin (VIP)]. ( Ebisui, K; Fujiwara, M; Kobayashi, T; Miyakoda, K; Nakagawa, S; Nakao, M; Nukui, M; Takada, H; Toyoda, K; Watanabe, H, 1989) |
| "Eleven patients with advanced adenocarcinoma of the prostate were treated with a cyclic alternating chemotherapy (VIP-DMF therapy), consisting of a three-drug combination of vincristine, ifosfamide, and peplomycin; and a three-drug combination of adriamycin, mitomycin C and 5-fluorouracil." | 3.67 | [Alternating combination chemotherapy (VIP-DMF) in patients with advanced adenocarcinoma of the prostate]. ( Akagi, T; Hara, M; Nanba, K; Obama, T; Ochi, J; Ozaki, Y; Saegusa, M; Tanahashi, T; Tsushima, T; Yoshimoto, J, 1987) |
| "Fifty-three patients with inoperable non-small cell bronchial carcinoma were treated at four-weekly intervals with two cytostatic drugs, doxorubicin (50 mg/m2 on day 1) and ifosfamide (2000 mg/m2 on days 1-3)." | 3.66 | [Combined cytostatic chemotherapy of advanced non-small-cell bronchial carcinoma with doxorubicin and ifosfamide]. ( Göbel, D; Matthiessen, W; Stempinski, E; Thalmann, U, 1983) |
| " Alternative dosing of glufosfamide plus gemcitabine should be explored." | 2.75 | A phase 2 trial of glufosfamide in combination with gemcitabine in chemotherapy-naive pancreatic adenocarcinoma. ( Barrios, CH; Chiorean, EG; Dragovich, T; Gorini, CF; Hamm, J; Jung, DT; Kroll, S; Langmuir, VK; Loehrer, PJ; Tidmarsh, GT, 2010) |
| "Phase I data indicate that full dose glufosfamide (4,500 mg/m(2)) can be given safely in combination with gemcitabine." | 2.73 | A Phase 1 dose-escalation trial of glufosfamide in combination with gemcitabine in solid tumors including pancreatic adenocarcinoma. ( Chiorean, EG; Colowick, AB; Dragovich, T; Hamm, J; Jung, DT; Kroll, S; Langmuir, VK; Loehrer, PJ; Tidmarsh, GF, 2008) |
| "Salvage chemotherapy in advanced ovarian cancer is not yet standardized." | 2.72 | Ifosfamide/mesna as salvage therapy in platinum pretreated ovarian cancer patients--long-term results of a phase II study. ( Baur, M; Dittrich, C; Fazeny-Doerner, B; Hudec, M; Salzer, H; Sevelda, P, 2006) |
| "Ifosfamide is an active alkylating agent used in the first-line treatment of NSCLC." | 2.71 | Phase II study of docetaxel and ifosfamide combination chemotherapy in non-small-cell lung cancer patients failing previous chemotherapy with or without paclitaxel. ( Chen, MC; Chen, YM; Lee, CS; Lin, WC; Perng, RP; Shih, JF; Tsai, CM, 2003) |
| "Secondary objectives were time to disease progression, response rates, evaluation of toxicity, disease-related symptoms, World Health Organization performance status (PS), and quality of life (QoL)." | 2.71 | Phase III trial of gemcitabine and carboplatin versus mitomycin, ifosfamide, and cisplatin or mitomycin, vinblastine, and cisplatin in patients with advanced nonsmall cell lung carcinoma. ( Anderson, H; Ashcroft, L; Beresford, C; Burt, PA; Clemons, M; Danson, S; Dowd, I; Fairve-Finn, C; Hassan, J; Middleton, MR; O'Byrne, KJ; Ranson, M; Stout, R; Thatcher, N, 2003) |
| "Ifosfamide is an active drug in the treatment of chemotherapy-naive patients with advanced endometrial cancer and its application in currently used (combination) regimens should be considered." | 2.69 | Cyclophosphamide or ifosfamide in patients with advanced and/or recurrent endometrial carcinoma: a randomized phase II study of the EORTC Gynecological Cancer Cooperative Group. ( Boes, GH; Cervantes, A; Hoesel, G; Pawinski, A; Pecorelli, S; Tumolo, S; van Oosterom, AT, 1999) |
| "Megestrol acetate 250 mg PO was administered throughout the duration of chemotherapy." | 2.69 | A brief intensive cisplatin-based outpatient chemotherapy regimen with filgrastim and megestrol acetate support for advanced non-small cell lung cancer: results of a phase II trial. ( Craffey, M; Dowlati, A; Levitan, N; MacKay, W; McKenney, J; Remick, SC; Tahsildar, H, 1998) |
| "Twenty-five women with advanced breast carcinoma refractory to first-line chemotherapy entered a phase II trial to evaluate the efficacy of ifosfamide and carboplatin." | 2.68 | Phase II clinical trial of carboplatin, ifosfamide, with oral mesna for metastatic breast carcinoma. ( Herman, RL; Kelley, AS; Muggia, FM; Russell, CA; Spicer, DV; Turrill, M, 1995) |
| "The ongoing phase I study reported here sought to determine the maximum tolerated doses of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) and carboplatin when given at specific times in combination with ifosfamide, mesna, and filgrastim." | 2.68 | Phase I trial of dose-escalated paclitaxel and carboplatin in combination with ifosfamide and filgrastim: preliminary results. ( Palackdharry, CS, 1997) |
| "The early stages of bronchial carcinoma are still a domain of operative treatment." | 2.68 | [Neoadjuvant radiochemotherapy in locally advanced non-small cell bronchial carcinoma. Initial results of a prospective multicenter study]. ( Klinke, F; Micke, O; Rübe, C; von Eiff, M; Wagner, W; Willich, N, 1995) |
| "Granulocytopenia was the dose-limiting toxicity." | 2.68 | Phase I study of paclitaxel, cisplatin, and ifosfamide in patients with recurrent or metastatic squamous cell cancer of the head and neck. ( Benner, SE; Hong, WK; Huber, MH; Lippman, SM, 1995) |
| "However, cancers such as ovarian cancer that form huge tumor masses cannot be cured completely with chemotherapy alone." | 2.66 | Current role of chemotherapy in the management of ovarian cancer. ( Yakushiji, M, 1987) |
| " A daily dosage of 50 to 60 mg/kg ifosfamide on 5 consecutive days produced the best results." | 2.64 | Evaluation of a cooperative clinical study of the cytostatic agent ifosfamide. ( Brock, N; Burkert, H; Fichtner, E; Schnitker, J, 1976) |
| "In epithelial ovarian cancer, responses were observed in eight (20%) of 41 evaluable patients, with three (7%) complete responses." | 2.38 | Gynecologic Oncology Group studies with ifosfamide. ( Blessing, JA; Homesley, H; Manetta, A; McGuire, W; Sutton, GP, 1992) |
| "Standard treatment of cervical cancer FIGO stage IB1 is a radical hysterectomy with pelvic lymphadenectomy." | 1.42 | Neoadjuvant chemotherapy followed by large cone resection as fertility-sparing therapy in stage IB cervical cancer. ( Leunen, K; Moerman, P; Neven, P; Salihi, R; Van Limbergen, E; Vergote, I, 2015) |
| "Downstaging by NAC in IB1 and IB2 cervical cancer before fertility-sparing surgery is still an experimental procedure, but shows some promise." | 1.40 | Oncological and pregnancy outcomes after high-dose density neoadjuvant chemotherapy and fertility-sparing surgery in cervical cancer. ( Halaska, MJ; Lisy, J; Matecha, J; Pluta, M; Rob, L; Robova, H; Skapa, P, 2014) |
| "In 20." | 1.35 | A retrospective study of patients with locally advanced cancer of the cervix treated with neoadjuvant chemotherapy followed by radical surgery. ( Doval, DC; Kumar, JV; Rao, R; Rawal, S, 2009) |
| "The patient died due to brain metastases 20 months after the start of intra-arterial chemotherapy." | 1.30 | [A case of metastatic liver tumors from prostatic cancer responding to intra-arterial infusion chemotherapy with CDDP and ifosfamide using implantable port]. ( Hasegawa, N; Kazama, A; Kondo, N; Tomita, M, 1999) |
| "The response rate was higher in squamous cell carcinomas (85%) than adenocarcinomas or adenosquamous carcinomas (67%)." | 1.30 | [Neoadjuvant chemotherapy for advanced cervical cancer]. ( Hongo, A; Ikuhashi, H; Kobashi, Y; Kodama, J; Kudo, T; Miyagi, Y; Mizutani, Y; Okuda, H; Yoshinouchi, M, 1999) |
| "Local control rate for inflammatory breast cancer (IBC) is < 50% with standard chemotherapy-radiotherapy regimen." | 1.30 | Inflammatory breast cancer: enhanced local control with hyperfractionated radiotherapy and infusional vincristine, ifosfamide and epirubicin. ( Boyages, J; Gurney, H; Harnett, P; Kefford, R, 1998) |
| "These were neuroepithelioma, lymphoma, desmoplastic small-cell tumor, melanoma, and clear-cell sarcoma." | 1.29 | Molecular and cytogenetic studies in the diagnosis of patients with poorly differentiated carcinomas of unknown primary site. ( Bosl, GJ; Chaganti, RS; Mazumdar, M; Motzer, RJ; Reuter, VE; Rodriguez, E, 1995) |
| "Ifosfamide has shown promising single-agent activity in non-small cell lung cancer (NSCLC)." | 1.28 | Phase II study of cisplatin, ifosfamide with mesna, and etoposide (PIE) chemotherapy for advanced non-small cell lung cancer. ( Dhingra, HH; Greenberg, J; Hong, WK; Lee, JS; Shirinian, M, 1992) |
| "Ifosfamide (IFX) has activity in a number of gynaecological malignancies and was selected for evaluation in this disease." | 1.28 | A phase II study of ifosfamide in endometrial cancer. ( Barton, C; Blackledge, G; Buxton, EJ; Meanwell, CA; Mould, JJ, 1990) |
| "The tumors included 5 squamous cell carcinomas (non keratinizing: 2, keratinizing: 3), two adenosquamous (including one glassy cell carcinoma), one adenocarcinoma (endometrioid type) and one argyrophil cell carcinoma." | 1.28 | Ifosfamide, adriamycin and cisplatin (IAP) plus bleomycin (B) combination chemotherapy in patients with recurrent cancer of the uterine cervix. ( Arimatsu, T; Izumi, S; Matsumura, T; Nagano, H; Nagasue, N; Nishida, T; Okura, N; Yakushiji, M, 1989) |
| "Ten patients with reactivated stage D prostatic cancer were treated with the combination therapy of vincristine, ifosfamide and peplomycin (VIP therapy)." | 1.27 | [Combination chemotherapy of vincristine, ifosfamide and peplomycin in patients with reactivated prostatic cancer]. ( Akiya, T; Katayama, T; Kazama, T; Nakada, T; Umeda, K, 1986) |
| "The course of 72 patients (36 with squamous carcinoma, 25 with adenocarcinoma, two with alveolar-cell carcinoma and nine with large-cell carcinoma) could be evaluated." | 1.27 | [Chemotherapy of the non-small cell carcinoma of the lung with ifosfamide and cisplatin]. ( Abel, U; Dirks, HP; Drings, P; Grimm, V; Heinrich, S; Kleckow, M; Manke, HG; Queisser, W; Stiefel, P, 1984) |
| "The most frequent histology was squamous cell carcinoma found in 20 patients." | 1.27 | [Chemotherapy with mitomycin C, vindesine and ifosfamide in the treatment of inoperable non-small cell bronchial carcinoma]. ( Gatzemeier, U; Hossfeld, DK; Radenbach, D; Zschaber, R, 1985) |
| "The etoposide combination was tolerated better." | 1.27 | Experience with ifosfamide combinations (etoposide or DDP) in non-small cell lung cancer. ( Abel, U; Bülzebruck, H; Drings, P; Kleckow, M; Manke, HG; Stiefel, P, 1986) |
| " Bone marrow suppression was the dose-limiting toxicity and led to dosage modification in 24 patients." | 1.27 | A phase II study of ifosfamide in advanced and relapsed carcinoma of the cervix. ( Coleman, RE; Gallagher, C; Harper, PG; Osborne, R; Rankin, EM; Silverstone, AC; Slevin, ML; Souhami, RL; Tobias, JS; Trask, CW, 1986) |
| "Ifosfamide was administered to 21 patients with recurrent or disseminated lung cancer at a dose of 4." | 1.26 | Ifosfamide in the treatment of recurrent or disseminated lung cancer: a phase II study of two dose schedules. ( Costanzi, JJ; Gagliano, R; Hokanson, JA; Loukas, D; Panettiere, FJ, 1978) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 43 (27.39) | 18.7374 |
| 1990's | 63 (40.13) | 18.2507 |
| 2000's | 34 (21.66) | 29.6817 |
| 2010's | 16 (10.19) | 24.3611 |
| 2020's | 1 (0.64) | 2.80 |
| Authors | Studies |
|---|---|
| Yonemaru, J | 1 |
| Takahashi, M | 1 |
| Nara, S | 1 |
| Ichikawa, H | 1 |
| Ishigamori, R | 1 |
| Imai, T | 1 |
| Hiraoka, N | 1 |
| Karageorgopoulou, S | 1 |
| Kostakis, ID | 1 |
| Gazouli, M | 1 |
| Markaki, S | 1 |
| Papadimitriou, M | 1 |
| Bournakis, E | 1 |
| Dimopoulos, MA | 2 |
| Papadimitriou, CA | 1 |
| Pinkavova, I | 1 |
| Fischerova, D | 1 |
| Zikan, M | 1 |
| Burgetova, A | 1 |
| Slama, J | 1 |
| Svarovsky, J | 1 |
| Dundr, P | 1 |
| Dusek, L | 1 |
| Cibula, D | 1 |
| Ozdemir, O | 1 |
| Ozdemir, P | 1 |
| Veral, A | 1 |
| Uluer, H | 1 |
| Ozhan, MH | 1 |
| Ma, K | 1 |
| Yang, YH | 1 |
| Yang, X | 1 |
| Feng, ZY | 1 |
| Liu, TY | 1 |
| Wen, HW | 1 |
| Liao, QP | 1 |
| Vizza, E | 1 |
| Corrado, G | 1 |
| Zanagnolo, V | 2 |
| Tomaselli, T | 1 |
| Cutillo, G | 1 |
| Mancini, E | 1 |
| Maggioni, A | 2 |
| Chovanec, M | 1 |
| Mego, M | 1 |
| Sycova-Mila, Z | 1 |
| Obertova, J | 1 |
| Rajec, J | 1 |
| Palacka, P | 1 |
| Mardiak, J | 1 |
| Robova, H | 1 |
| Halaska, MJ | 1 |
| Pluta, M | 1 |
| Skapa, P | 1 |
| Matecha, J | 1 |
| Lisy, J | 1 |
| Rob, L | 1 |
| Gakis, G | 1 |
| Morgan, TM | 1 |
| Daneshmand, S | 1 |
| Keegan, KA | 1 |
| Todenhöfer, T | 1 |
| Mischinger, J | 1 |
| Schubert, T | 1 |
| Zaid, HB | 1 |
| Hrbacek, J | 1 |
| Ali-El-Dein, B | 1 |
| Clayman, RH | 1 |
| Galland, S | 1 |
| Olugbade, K | 1 |
| Rink, M | 1 |
| Fritsche, HM | 1 |
| Burger, M | 1 |
| Chang, SS | 1 |
| Babjuk, M | 1 |
| Thalmann, GN | 1 |
| Stenzl, A | 1 |
| Efstathiou, JA | 1 |
| Salihi, R | 1 |
| Leunen, K | 1 |
| Van Limbergen, E | 1 |
| Moerman, P | 1 |
| Neven, P | 1 |
| Vergote, I | 1 |
| Minig, L | 1 |
| Cárdenas-Rebollo, JM | 1 |
| Colombo, N | 1 |
| Tatokoro, M | 1 |
| Kawakami, S | 1 |
| Yonese, J | 1 |
| Fujii, Y | 1 |
| Okubo, Y | 1 |
| Yamamoto, S | 1 |
| Takeshita, H | 1 |
| Komai, Y | 1 |
| Ishikawa, Y | 1 |
| Fukui, I | 2 |
| Maneo, A | 1 |
| Chiari, S | 1 |
| Bonazzi, C | 1 |
| Mangioni, C | 1 |
| Li, XP | 1 |
| Cui, H | 1 |
| Zhou, JW | 1 |
| Wei, LH | 1 |
| Wang, JL | 1 |
| Zhao, Y | 1 |
| Wang, Y | 1 |
| Wang, SJ | 1 |
| Zhu, HL | 1 |
| Dong, L | 1 |
| Zhang, H | 1 |
| Ciuleanu, TE | 1 |
| Pavlovsky, AV | 1 |
| Bodoky, G | 1 |
| Garin, AM | 1 |
| Langmuir, VK | 3 |
| Kroll, S | 3 |
| Tidmarsh, GT | 2 |
| Mesa, H | 1 |
| Rawal, A | 1 |
| Rezcallah, A | 1 |
| Iwamoto, C | 1 |
| Niehans, GA | 1 |
| Druck, P | 1 |
| Gupta, P | 1 |
| Kumar, JV | 1 |
| Doval, DC | 1 |
| Rao, R | 1 |
| Rawal, S | 1 |
| Chiorean, EG | 2 |
| Dragovich, T | 2 |
| Hamm, J | 2 |
| Barrios, CH | 1 |
| Gorini, CF | 1 |
| Jung, DT | 2 |
| Loehrer, PJ | 6 |
| Chu, P | 1 |
| Lu, CH | 1 |
| Sheng, XG | 1 |
| Zhou, CX | 1 |
| Li, DP | 1 |
| DU, XL | 1 |
| Liu, NF | 1 |
| Gong, L | 1 |
| Lou, JY | 1 |
| Wang, P | 1 |
| Zhang, JW | 1 |
| Liu, H | 1 |
| Peng, ZL | 1 |
| Wang, PL | 1 |
| Cheng, YB | 1 |
| Kuerban, G | 1 |
| Vercellino, GF | 1 |
| Piek, JM | 1 |
| Schneider, A | 1 |
| Köhler, C | 1 |
| Mangler, M | 1 |
| Speiser, D | 1 |
| Chiantera, V | 1 |
| Vitobello, D | 1 |
| Siesto, G | 1 |
| Pirovano, C | 1 |
| Ieda, N | 1 |
| Hervonen, P | 1 |
| Lehtinen, T | 1 |
| Tammela, TL | 1 |
| Kellokumpu-Lehtinen, P | 1 |
| Blot, E | 1 |
| Decaudin, D | 1 |
| Veyradier, A | 1 |
| Bardier, A | 1 |
| Zagame, OL | 1 |
| Pouillart, P | 2 |
| Marx, G | 1 |
| Lewis, C | 1 |
| Hall, K | 1 |
| Levi, J | 1 |
| Ackland, S | 1 |
| Siersema, PD | 1 |
| Hage, M | 1 |
| van der Gaast, A | 2 |
| van Dekken, H | 1 |
| Kok, TC | 2 |
| Tilanus, HW | 2 |
| Kuipers, EJ | 1 |
| Gebbia, V | 1 |
| Galetta, D | 1 |
| Caruso, M | 1 |
| Verderame, F | 1 |
| Pezzella, G | 1 |
| Valdesi, M | 1 |
| Borsellino, N | 1 |
| Pandolfo, G | 1 |
| Durini, E | 1 |
| Rinaldi, M | 1 |
| Loizzi, M | 1 |
| Gebbia, N | 1 |
| Valenza, R | 1 |
| Tirrito, ML | 1 |
| Varvara, F | 1 |
| Colucci, G | 1 |
| Chen, YM | 1 |
| Shih, JF | 1 |
| Lee, CS | 1 |
| Chen, MC | 1 |
| Lin, WC | 2 |
| Tsai, CM | 2 |
| Perng, RP | 2 |
| Salmons, B | 5 |
| Löhr, M | 4 |
| Günzburg, WH | 5 |
| Danson, S | 1 |
| Middleton, MR | 1 |
| O'Byrne, KJ | 1 |
| Clemons, M | 1 |
| Ranson, M | 1 |
| Hassan, J | 1 |
| Anderson, H | 1 |
| Burt, PA | 1 |
| Fairve-Finn, C | 1 |
| Stout, R | 1 |
| Dowd, I | 1 |
| Ashcroft, L | 2 |
| Beresford, C | 1 |
| Thatcher, N | 3 |
| Fujita, A | 4 |
| Ohkubo, T | 1 |
| Hoshino, H | 1 |
| Takabatake, H | 3 |
| Tagaki, S | 3 |
| Sekine, K | 4 |
| Abe, S | 1 |
| Briasoulis, E | 1 |
| Pavlidis, N | 1 |
| Terret, C | 1 |
| Bauer, J | 1 |
| Fiedler, W | 1 |
| Schöffski, P | 1 |
| Raoul, JL | 1 |
| Hess, D | 1 |
| Selvais, R | 1 |
| Lacombe, D | 1 |
| Bachmann, P | 1 |
| Fumoleau, P | 1 |
| Junker, K | 1 |
| Müller, KM | 1 |
| Abker, S | 1 |
| Bosse, U | 1 |
| Klinke, F | 2 |
| Thomas, M | 1 |
| Boutemy, M | 1 |
| Mispelaere, D | 1 |
| Krzisch, C | 1 |
| Jounieaux, V | 1 |
| Vrdoljak, E | 1 |
| Boraska Jelavic, T | 1 |
| Saratlija-Novakovic, Z | 1 |
| Hamm, W | 1 |
| Baur, M | 1 |
| Fazeny-Doerner, B | 1 |
| Hudec, M | 1 |
| Sevelda, P | 1 |
| Salzer, H | 1 |
| Dittrich, C | 1 |
| Markman, M | 1 |
| Galsky, MD | 1 |
| Iasonos, A | 1 |
| Mironov, S | 1 |
| Scattergood, J | 1 |
| Donat, SM | 1 |
| Bochner, BH | 1 |
| Herr, HW | 1 |
| Russo, P | 1 |
| Boyle, MG | 1 |
| Bajorin, DF | 1 |
| Colowick, AB | 1 |
| Tidmarsh, GF | 1 |
| Booton, R | 1 |
| Ward, T | 1 |
| Morris, J | 1 |
| Heighway, J | 1 |
| Han, JQ | 1 |
| Han, CY | 1 |
| Bi, YH | 1 |
| Arai, H | 1 |
| Rino, Y | 1 |
| Yamanaka, S | 2 |
| Yukawa, N | 1 |
| Wada, N | 1 |
| Kudo, M | 1 |
| Watanuki, Y | 1 |
| Fukumura, H | 1 |
| Nakajima, K | 1 |
| Oshiro, H | 1 |
| Masuda, M | 1 |
| Drings, P | 4 |
| Stiefel, P | 3 |
| Dirks, HP | 1 |
| Grimm, V | 1 |
| Kleckow, M | 2 |
| Manke, HG | 3 |
| Queisser, W | 1 |
| Abel, U | 2 |
| Heinrich, S | 1 |
| Saiers, JH | 2 |
| Slavik, M | 2 |
| Harrison, EF | 1 |
| Hawke, JE | 1 |
| Hunter, HL | 1 |
| Costanzi, JJ | 3 |
| Morgan, LR | 2 |
| Plotkin, D | 1 |
| Tucker, WG | 1 |
| Worrall, PM | 1 |
| Hokanson, J | 1 |
| Holoye, PY | 2 |
| Anderson, T | 2 |
| Duelge, J | 2 |
| Hansen, RM | 2 |
| Ritch, PS | 2 |
| Bakowski, MT | 1 |
| Crouch, JC | 1 |
| Joss, RA | 1 |
| Cavalli, F | 1 |
| Goldhirsch, A | 2 |
| Mermillod, B | 1 |
| Brunner, KW | 2 |
| Nishida, T | 6 |
| Oda, T | 2 |
| Sugiyama, T | 2 |
| Iwanaga, S | 1 |
| Katabuchi, H | 2 |
| Araki, T | 2 |
| Struck, RF | 1 |
| Dykes, DJ | 1 |
| Corbett, TH | 1 |
| Suling, WJ | 1 |
| Trader, MW | 1 |
| Williams, SD | 3 |
| Einhorn, LH | 3 |
| Matthiessen, W | 1 |
| Stempinski, E | 1 |
| Göbel, D | 1 |
| Thalmann, U | 1 |
| Kohno, I | 1 |
| Kazuta, M | 1 |
| Miyao, J | 1 |
| Kunimi, N | 1 |
| Kawamoto, M | 1 |
| Tanimura, T | 1 |
| Fujiwara, K | 1 |
| Sekiba, K | 1 |
| Satomi, Y | 1 |
| Kawamura, N | 1 |
| Yakushiji, M | 4 |
| Tsunawaki, A | 1 |
| Nishimura, H | 1 |
| Natsuaki, Y | 1 |
| Inoue, T | 1 |
| Kato, T | 2 |
| König, HJ | 1 |
| Hartwich, G | 1 |
| Benner, SE | 1 |
| Lippman, SM | 1 |
| Huber, MH | 1 |
| Hong, WK | 2 |
| Wagner, W | 1 |
| von Eiff, M | 1 |
| Micke, O | 1 |
| Rübe, C | 1 |
| Willich, N | 1 |
| Motzer, RJ | 1 |
| Rodriguez, E | 1 |
| Reuter, VE | 1 |
| Bosl, GJ | 1 |
| Mazumdar, M | 1 |
| Chaganti, RS | 1 |
| Turrill, M | 1 |
| Spicer, DV | 1 |
| Kelley, AS | 1 |
| Herman, RL | 1 |
| Russell, CA | 1 |
| Muggia, FM | 1 |
| Fanning, J | 1 |
| Ladd, C | 1 |
| Hilgers, RD | 1 |
| Sutton, GP | 4 |
| Blessing, JA | 4 |
| Homesley, HD | 1 |
| McGuire, WP | 2 |
| Adcock, L | 1 |
| Hartley, JM | 1 |
| Hansen, L | 1 |
| Harland, SJ | 1 |
| Nicholson, PW | 1 |
| Pasini, F | 1 |
| Souhami, RL | 2 |
| Ushiyama, T | 1 |
| Ihara, H | 1 |
| Kurita, Y | 1 |
| Kageyama, S | 1 |
| Ueda, D | 1 |
| Mugiya, S | 1 |
| Yamaguchi, Y | 1 |
| Nakano, M | 1 |
| Suzuki, K | 1 |
| Kawabe, K | 1 |
| Wils, JA | 1 |
| Kok, T | 1 |
| Wagener, DJ | 1 |
| Francois, E | 1 |
| Selleslags, J | 1 |
| Duez, N | 2 |
| Darnton, SJ | 5 |
| Allen, SM | 2 |
| Edwards, CW | 1 |
| Matthews, HR | 4 |
| DiSaia, PJ | 1 |
| Dorval, T | 1 |
| Beuzeboc, P | 1 |
| Garcia-Giralt, E | 1 |
| Jouve, M | 1 |
| Livartowski, A | 1 |
| Palangie, T | 1 |
| Jenner, K | 1 |
| Steyn, RS | 1 |
| Ferry, DR | 2 |
| Duffy, JP | 1 |
| Cullen, MH | 1 |
| Souquet, PJ | 1 |
| Fournel, P | 1 |
| Bohas, CH | 1 |
| Fortune, IC | 1 |
| Chatte, G | 1 |
| Di Costanzo, F | 1 |
| Tagliaventi, M | 1 |
| Carlini, P | 1 |
| Zironi, S | 1 |
| Mazzocchi, B | 1 |
| Bella, M | 1 |
| Donati, D | 1 |
| Acito, L | 1 |
| Maggian, P | 1 |
| Angiona, S | 1 |
| Nardi, M | 1 |
| Della Giulia, M | 1 |
| Pollera, CF | 1 |
| Marolla, P | 1 |
| Ruggeri, EM | 1 |
| Iacovelli, A | 1 |
| Atlante, G | 1 |
| Calabresi, F | 1 |
| Perkins, JB | 1 |
| Effenbein, GJ | 1 |
| Fields, KK | 1 |
| Williamson, SK | 1 |
| Wolf, MK | 1 |
| Eisenberger, MA | 1 |
| O'Rourke, MA | 1 |
| Brannon, W | 1 |
| Crawford, ED | 1 |
| Vansteenkiste, J | 1 |
| Vandebroek, J | 1 |
| Mariën, S | 1 |
| Roex, L | 1 |
| Bertrand, P | 1 |
| Bockaert, J | 1 |
| De Beukelaar, T | 1 |
| Deman, R | 1 |
| De Muynck, P | 1 |
| Ulrichts, H | 1 |
| Lokich, J | 1 |
| Anderson, N | 1 |
| Moore, C | 1 |
| Bern, M | 1 |
| Coco, F | 1 |
| Dow, E | 1 |
| Poorter, RL | 1 |
| Bakker, PJ | 1 |
| Huizing, MT | 1 |
| Taat, CW | 1 |
| Rietbroek, RC | 1 |
| Gouma, DJ | 1 |
| Rauws, EA | 1 |
| Veenhof, CH | 1 |
| Teicher, BA | 1 |
| Holden, SA | 1 |
| Goff, DA | 1 |
| Wright, JE | 1 |
| Tretyakov, O | 1 |
| Ayash, LJ | 1 |
| Scagliotti, GV | 1 |
| Ricardi, U | 1 |
| Crinó, L | 1 |
| Maranzano, E | 1 |
| De Marinis, F | 1 |
| Morandi, MG | 1 |
| Meacci, L | 1 |
| Marangolo, M | 1 |
| Emiliani, E | 1 |
| Rosti, G | 1 |
| Figoli, F | 1 |
| Bolzicco, G | 1 |
| Masiero, P | 1 |
| Gentile, A | 1 |
| Tonato, M | 1 |
| DeMars, LR | 1 |
| Moore, D | 1 |
| Burke, TW | 1 |
| Grendys, EC | 1 |
| Dreicer, R | 1 |
| Propert, KJ | 1 |
| Roth, BJ | 1 |
| Rodenhuis, S | 1 |
| Boerrigter, L | 1 |
| Top, B | 1 |
| Slebos, RJ | 1 |
| Mooi, WJ | 1 |
| van't Veer, L | 1 |
| van Zandwijk, N | 1 |
| Palackdharry, CS | 1 |
| Witschi, H | 1 |
| Espiritu, I | 1 |
| Peake, JL | 1 |
| Wu, K | 1 |
| Maronpot, RR | 1 |
| Pinkerton, KE | 1 |
| Kyriakakis, Z | 1 |
| Kostakopoulos, A | 1 |
| Karayiannis, A | 1 |
| Sofras, F | 1 |
| Zervas, A | 1 |
| Giannopoulos, A | 1 |
| Dimopoulos, C | 1 |
| Malhaire, JP | 1 |
| Labat, JP | 1 |
| Simon, H | 1 |
| Le Maux, H | 1 |
| Spindler, P | 1 |
| Lucas, B | 1 |
| Lamezec, B | 1 |
| Haberkorn, U | 1 |
| Krems, B | 1 |
| Gerlach, L | 1 |
| Bachert, P | 1 |
| Morr, I | 1 |
| Wiessler, M | 1 |
| van Kaick, G | 1 |
| Gurney, H | 2 |
| Harnett, P | 1 |
| Kefford, R | 1 |
| Boyages, J | 1 |
| Kodama, J | 1 |
| Ikuhashi, H | 1 |
| Hongo, A | 1 |
| Mizutani, Y | 1 |
| Miyagi, Y | 1 |
| Yoshinouchi, M | 1 |
| Kobashi, Y | 1 |
| Okuda, H | 1 |
| Kudo, T | 1 |
| Karle, P | 4 |
| Müller, P | 3 |
| Renz, R | 1 |
| Jesnowski, R | 2 |
| Saller, R | 1 |
| von Rombs, K | 1 |
| Nizze, H | 3 |
| Liebe, S | 3 |
| Levitan, N | 1 |
| Dowlati, A | 1 |
| Craffey, M | 1 |
| Tahsildar, H | 1 |
| MacKay, W | 1 |
| McKenney, J | 1 |
| Remick, SC | 1 |
| Stange, J | 1 |
| Mitzner, S | 1 |
| Nebe, B | 1 |
| Waller, CF | 1 |
| von Lintig, F | 1 |
| Daskalakis, A | 1 |
| Musahl, V | 1 |
| Lange, W | 1 |
| Kondo, N | 1 |
| Tomita, M | 1 |
| Hasegawa, N | 1 |
| Kazama, A | 1 |
| Pawinski, A | 1 |
| Tumolo, S | 1 |
| Hoesel, G | 1 |
| Cervantes, A | 1 |
| van Oosterom, AT | 1 |
| Boes, GH | 1 |
| Pecorelli, S | 1 |
| Campisi, C | 1 |
| Fabi, A | 1 |
| Papaldo, P | 1 |
| Tomao, S | 1 |
| Massidda, B | 1 |
| Zappala, A | 1 |
| Ionta, MT | 1 |
| Cognetti, F | 1 |
| Kusnierczyk, H | 1 |
| Pajtasz-Piasecka, E | 1 |
| Radzikowski, C | 1 |
| Chen, Y | 1 |
| Yang, KY | 1 |
| Wu, HW | 1 |
| Whang-Peng, J | 1 |
| Renner, M | 2 |
| Hoffmeyer, A | 1 |
| Kröger, J | 1 |
| Freund, M | 1 |
| Hain, J | 1 |
| Holle, A | 1 |
| Knöfel, WT | 1 |
| Saller, RM | 1 |
| Wagner, T | 1 |
| Hauenstein, K | 1 |
| Saghatchian, M | 1 |
| Fizazi, K | 1 |
| Borel, C | 1 |
| Ducreux, M | 1 |
| Ruffié, P | 1 |
| Le Chevalier, T | 1 |
| Théodore, C | 1 |
| Blohmer, JU | 1 |
| Paepke, S | 1 |
| Böhmer, D | 1 |
| Ernhardt, B | 1 |
| Sehouli, J | 1 |
| Elling, D | 1 |
| Lichtenegger, W | 1 |
| Archer, VR | 1 |
| Mulholland, PJ | 1 |
| Stocken, DD | 1 |
| Tilignac, T | 1 |
| Temparis, S | 1 |
| Combaret, L | 1 |
| Taillandier, D | 1 |
| Pouch, MN | 1 |
| Cervek, M | 1 |
| Cardenas, DM | 1 |
| Le Bricon, T | 1 |
| Debiton, E | 1 |
| Samuels, SE | 1 |
| Madelmont, JC | 1 |
| Attaix, D | 1 |
| Gagliano, R | 1 |
| Loukas, D | 1 |
| Panettiere, FJ | 1 |
| Hokanson, JA | 1 |
| Issell, BF | 1 |
| Valdivieso, M | 1 |
| Hersh, EM | 1 |
| Richman, S | 1 |
| Gutterman, JU | 1 |
| Bodey, GP | 1 |
| Schnitker, J | 1 |
| Brock, N | 1 |
| Burkert, H | 1 |
| Fichtner, E | 1 |
| Tay, SK | 1 |
| Lai, FM | 1 |
| Soh, LT | 1 |
| Ho, TH | 1 |
| Ang, PT | 1 |
| Au, E | 1 |
| Shirinian, M | 1 |
| Lee, JS | 1 |
| Dhingra, HH | 1 |
| Greenberg, J | 1 |
| Hirabayashi, K | 1 |
| Okada, E | 1 |
| Nakazuma, Y | 1 |
| Akamatsu, Y | 1 |
| Sezaki, H | 1 |
| Ohta, M | 1 |
| Nakanishi, Y | 1 |
| Antonakopoulos, GN | 1 |
| Newman, J | 1 |
| Hojo, K | 1 |
| Kumasaka, Y | 1 |
| Nishiyama, S | 1 |
| Higashihara, T | 1 |
| Oku, Y | 1 |
| Okada, M | 1 |
| Kajiyama, K | 1 |
| Manetta, A | 1 |
| Homesley, H | 1 |
| McGuire, W | 1 |
| de Campos, ES | 1 |
| Dodwell, D | 1 |
| Kamthan, A | 1 |
| Ohnoshi, T | 3 |
| Ueoka, H | 3 |
| Kodani, T | 1 |
| Kamei, H | 1 |
| Kimura, I | 1 |
| Buxton, EJ | 2 |
| Saunders, N | 1 |
| Blackledge, GR | 1 |
| Kelly, K | 1 |
| Redman, CW | 1 |
| Monaghan, J | 1 |
| Paterson, ME | 1 |
| Luesley, DM | 1 |
| Vannier, JP | 1 |
| Flamant, F | 1 |
| Hemet, J | 1 |
| Caillaud, JM | 1 |
| Gruner, M | 1 |
| Bachy, B | 1 |
| Lefur, R | 1 |
| Lemerle, J | 1 |
| Tron, P | 1 |
| Cerny, T | 1 |
| Martinelli, G | 1 |
| Terrier, F | 1 |
| Joss, R | 1 |
| Fey, MF | 1 |
| Küpfer, A | 1 |
| Klein, HO | 1 |
| Golbach, G | 1 |
| Voigt, P | 1 |
| Coerper, C | 1 |
| Bernhardt, C | 1 |
| Splinter, TA | 1 |
| Sasaki, H | 1 |
| Mori, T | 1 |
| Nakajima, S | 1 |
| Inoue, Y | 1 |
| Honda, R | 1 |
| Asakawa, M | 1 |
| Suzuki, A | 1 |
| Ulmer, W | 1 |
| Anderson, NR | 1 |
| Tandon, DS | 1 |
| Abad, A | 1 |
| Rosell, R | 1 |
| Barnadas, A | 1 |
| Carles, J | 1 |
| Ribelles, N | 1 |
| Solano, V | 1 |
| Fujii, M | 1 |
| Segawa, Y | 1 |
| Matsutomo, S | 1 |
| Genba, K | 1 |
| Paccagnella, A | 1 |
| Favaretto, A | 1 |
| Brandes, A | 1 |
| Ghiotto, C | 1 |
| Fornasiero, A | 1 |
| Volpi, A | 1 |
| Pappagallo, G | 1 |
| Festi, G | 1 |
| Cipriani, A | 1 |
| Vinante, O | 1 |
| Barton, C | 1 |
| Blackledge, G | 1 |
| Mould, JJ | 1 |
| Meanwell, CA | 1 |
| Yoshimoto, J | 2 |
| Nasu, Y | 1 |
| Akagi, T | 2 |
| Obama, T | 2 |
| Tsushima, T | 2 |
| Ozaki, Y | 2 |
| Matsumura, Y | 1 |
| Ohmori, H | 1 |
| Kazama, T | 1 |
| Katayama, T | 1 |
| Umeda, K | 1 |
| Akiya, T | 1 |
| Nakada, T | 1 |
| Ochi, J | 1 |
| Tanahashi, T | 1 |
| Nanba, K | 1 |
| Saegusa, M | 1 |
| Hara, M | 1 |
| Nukui, M | 1 |
| Nakao, M | 1 |
| Nakagawa, S | 1 |
| Toyoda, K | 1 |
| Takada, H | 1 |
| Ebisui, K | 1 |
| Watanabe, H | 1 |
| Miyakoda, K | 1 |
| Kobayashi, T | 1 |
| Fujiwara, M | 1 |
| Nagasue, N | 2 |
| Arimatsu, T | 1 |
| Nagano, H | 1 |
| Izumi, S | 1 |
| Okura, N | 1 |
| Matsumura, T | 1 |
| Numata, T | 1 |
| Kawahara, S | 2 |
| Nishii, K | 1 |
| Yonei, T | 2 |
| Yamashita, H | 2 |
| Ishii, J | 2 |
| Moritaka, T | 1 |
| Kiura, K | 1 |
| Meier, W | 1 |
| Eiermann, W | 1 |
| Stieber, P | 1 |
| Fateh-Moghadam, A | 1 |
| Hepp, H | 1 |
| Wils, J | 1 |
| Bleiberg, H | 1 |
| Buyse, M | 1 |
| Wagener, DT | 1 |
| Splinter, T | 1 |
| Veenhof, C | 1 |
| Herben, M | 1 |
| Takeuchi, S | 1 |
| Higashi, Y | 1 |
| Andoh, M | 1 |
| Kihara, K | 1 |
| Kitahara, S | 1 |
| Horiuchi, S | 1 |
| Oshima, H | 1 |
| Ardizzoni, A | 1 |
| Fusco, V | 1 |
| Gulisano, M | 1 |
| Pronzato, P | 1 |
| Baracco, F | 1 |
| Capaccio, A | 1 |
| Pastorino, G | 1 |
| Nosenzo, M | 1 |
| Felletti, R | 1 |
| Fabiano, F | 1 |
| Hiraki, S | 1 |
| Tamura, T | 1 |
| Tamai, M | 1 |
| Egawa, T | 1 |
| Becker, H | 1 |
| Bülzebruck, H | 2 |
| Djawid, N | 1 |
| Ruchalla, E | 1 |
| Tessen, HW | 1 |
| Satoh, H | 1 |
| Yano, H | 1 |
| Naitoh, T | 1 |
| Suyama, T | 1 |
| Takahashi, N | 1 |
| Kameyama, M | 1 |
| Satoh, T | 1 |
| Ohtsuka, M | 1 |
| Yoshizawa, Y | 1 |
| Hasegawa, S | 1 |
| Gatzemeier, U | 1 |
| Hossfeld, DK | 1 |
| Radenbach, D | 1 |
| Zschaber, R | 1 |
| Nichols, CR | 1 |
| Coleman, RE | 1 |
| Harper, PG | 1 |
| Gallagher, C | 1 |
| Osborne, R | 1 |
| Rankin, EM | 1 |
| Silverstone, AC | 1 |
| Slevin, ML | 1 |
| Tobias, JS | 1 |
| Trask, CW | 1 |
| Kamura, N | 1 |
| Ansari, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Open Label Phase II Study on Glufosfamide Administered as a 60 Minute Infusion Every 3 Weeks in Advanced Pancreatic Cancer[NCT00005053] | Phase 2 | 35 participants (Actual) | Interventional | 1999-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for ifosfamide and Adenocarcinoma, Basal Cell
| Article | Year |
|---|---|
[Clinical features of patients with metastasis in phalanges as first symptom of primary lung cancer].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcino | 2007 |
Chemotherapy of non-small cell lung cancer: a reappraisal and a look to the future.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Sm | 1983 |
New agents in non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Alkylating Agents; Animals; Anthraquinones; Antibiotics, Antineoplastic; Anti | 1984 |
Gynecologic Oncology Group studies with ifosfamide.
Topics: Adenocarcinoma; Carcinoma; Clinical Trials, Phase II as Topic; Endometrial Neoplasms; Female; Genita | 1992 |
60 trials available for ifosfamide and Adenocarcinoma, Basal Cell
| Article | Year |
|---|---|
Prognostic and predictive factors in patients with metastatic or recurrent cervical cancer treated with platinum-based chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carc | 2017 |
[Efficacy and tolerability of the combination of oxaliplatin, ifosfamide, and epirubicin in treatment of recurrent or platinum-resistant ovarian epithelial cancer patients].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; | 2008 |
A randomised Phase III trial of glufosfamide compared with best supportive care in metastatic pancreatic adenocarcinoma previously treated with gemcitabine.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Deoxycytidine; Fe | 2009 |
A phase 2 trial of glufosfamide in combination with gemcitabine in chemotherapy-naive pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; | 2010 |
[Gemcitabine based combination chemotherapy, a new salvage regimen for recurrent platinum resistant epithelial ovarian cancer].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Resistanc | 2010 |
A randomised dose-finding phase II study on ifosfamide in metastatic hormone-refractory prostate cancer (HRPC).
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Alkylating; Bone Neoplasms; Disease Progression; Dose-R | 2002 |
Phase I study of docetaxel plus ifosfamide in patients with advanced cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Dose-Respons | 2002 |
Gemcitabine and cisplatin versus vinorelbine and cisplatin versus ifosfamide+gemcitabine followed by vinorelbine and cisplatin versus vinorelbine and cisplatin followed by ifosfamide and gemcitabine in stage IIIB-IV non small cell lung carcinoma: a prospe
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; | 2003 |
Phase II study of docetaxel and ifosfamide combination chemotherapy in non-small-cell lung cancer patients failing previous chemotherapy with or without paclitaxel.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy | 2003 |
Treatment of inoperable pancreatic carcinoma using a cell-based local chemotherapy: results of a phase I/II clinical trial.
Topics: Adenocarcinoma; Antineoplastic Agents, Alkylating; Cell Transplantation; Cytochrome P-450 CYP2B1; Do | 2003 |
Phase III trial of gemcitabine and carboplatin versus mitomycin, ifosfamide, and cisplatin or mitomycin, vinblastine, and cisplatin in patients with advanced nonsmall cell lung carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anxiety; Carboplatin; C | 2003 |
Phase II study of cisplatin, ifosfamide, and irinotecan with rhG-CSF support in patients with stage IIIb and IV non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma | 2003 |
Glufosfamide administered using a 1-hour infusion given as first-line treatment for advanced pancreatic cancer. A phase II trial of the EORTC-new drug development group.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Disease Progression; Disease-Free Survival; Fema | 2003 |
Ifosfamide/mesna as salvage therapy in platinum pretreated ovarian cancer patients--long-term results of a phase II study.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Female; | 2006 |
Prospective trial of ifosfamide, paclitaxel, and cisplatin in patients with advanced non-transitional cell carcinoma of the urothelial tract.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biop | 2007 |
A Phase 1 dose-escalation trial of glufosfamide in combination with gemcitabine in solid tumors including pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic | 2008 |
ERCC1 mRNA expression is not associated with response and survival after platinum-based chemotherapy regimens in advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; | 2007 |
Single-dose ifosfamide: efficacy studies in non-small cell lung cancer.
Topics: Actuarial Analysis; Adenocarcinoma; Adult; Aged; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cl | 1982 |
Use and safety of high-dose ifosfamide.
Topics: Adenocarcinoma; Aged; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Clinical Trials as Topic; Cyc | 1982 |
Chemotherapy of non-small cell lung cancer: a reappraisal and a look to the future.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Sm | 1983 |
New agents in non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Alkylating Agents; Animals; Anthraquinones; Antibiotics, Antineoplastic; Anti | 1984 |
Phase I study of paclitaxel, cisplatin, and ifosfamide in patients with recurrent or metastatic squamous cell cancer of the head and neck.
Topics: Adenocarcinoma; Adult; Aged; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Carcin | 1995 |
[Neoadjuvant radiochemotherapy in locally advanced non-small cell bronchial carcinoma. Initial results of a prospective multicenter study].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Brain; Carboplatin; Carcinoma, Bronc | 1995 |
Phase II clinical trial of carboplatin, ifosfamide, with oral mesna for metastatic breast carcinoma.
Topics: Adenocarcinoma; Adult; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Breast Neopl | 1995 |
Cisplatin, 5-fluorouracil, and ifosfamide in the treatment of recurrent or advanced cervical cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 1995 |
Phase II study of ifosfamide and mesna in refractory adenocarcinoma of the endometrium. A Gynecologic Oncology Group study.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Combined Modality Therapy; Endometrial Neoplasms; Female; H | 1994 |
[Results of combination chemotherapy with etoposide, ifosfamide, peplomycin for advanced prostatic cancer].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Diethylstilbestrol; Drug Admin | 1993 |
Phase II trial with ifosfamide in pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Female; Humans; Ifosfamide; Male; Middle Aged; Pancreatic Neoplasms | 1993 |
Phase II study of ifosfamide and mesna in nonsquamous carcinoma of the cervix: a Gynecologic Oncology Group study.
Topics: Adenocarcinoma; Adult; Aged; Carcinoma; Female; Humans; Ifosfamide; Mesna; Middle Aged; Uterine Cerv | 1993 |
[Treatment of cancers of the ovary. Phase II trial of increase of the dose of cisplatin].
Topics: Adenocarcinoma; Adult; Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; | 1993 |
Phase II study of mitomycin, ifosfamide and cisplatin in adenocarcinoma of the oesophagus.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 1996 |
Cisplatin and ifosfamide with various doses of vinorelbine (navelbine) in advanced non-small lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplasti | 1996 |
High-dose folinic acid and fluorouracil with or without ifosfamide is an inactive combination in advanced pancreatic cancer. A randomized phase II study of the Italian Oncology Group for Clinical Research (G.O.I.R.C.).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; H | 1996 |
A combination of ifosfamide and mitoxantrone as salvage therapy in patients with advanced ovarian cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 1996 |
Analysis of dose-response relationships in the setting of high-dose ifosfamide, carboplatin, and etoposide and autologous hematopoietic stem cell transplantation: implications for the treatment of patients with advanced breast cancer.
Topics: Adenocarcinoma; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylatin | 1996 |
Phase II evaluation of ifosfamide/mesna in metastatic prostate cancer. A Southwest Oncology Group study.
Topics: Adenocarcinoma; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; B | 1996 |
Combination chemotherapy with vindesine-ifosfamide-cisplatin (VIP) in locally advanced unresectable stage III and in stage IV non-small cell lung cancer: a phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; | 1995 |
Pilot study of ambulatory infusional delivery of a multidrug regimen: ifosfamide, carboplatin and etoposide (ICE).
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Ambulatory Care; Anemia; Antineoplastic Combined Che | 1996 |
Phase II study of intensive chemotherapy with carboplatin, ifosfamide and etoposide plus recombinant human granulocyte colony-stimulating factor and sequential radiotherapy in locally advanced, unresectable non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, | 1996 |
A phase II Gynecologic Oncology Group trial of ifosfamide and mesna in advanced or recurrent adenocarcinoma of the endometrium.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Drug Therapy, Combination; Endometrial Neoplasms; Fe | 1996 |
Vinblastine, ifosfamide, and gallium nitrate--an active new regimen in patients with advanced carcinoma of the urothelium. A phase II trial of the Eastern Cooperative Oncology Group (E5892).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional | 1997 |
Phase I trial of dose-escalated paclitaxel and carboplatin in combination with ifosfamide and filgrastim: preliminary results.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Carci | 1997 |
Cisplatin, ifosfamide, methotrexate and vinblastine combination chemotherapy for metastatic urothelial cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic A | 1997 |
A brief intensive cisplatin-based outpatient chemotherapy regimen with filgrastim and megestrol acetate support for advanced non-small cell lung cancer: results of a phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Appetite Stimulants; Ca | 1998 |
Mobilization of peripheral blood progenitor cells in patients with breast cancer: a prospective randomized trial comparing rhG-CSF with the combination of rhG-CSF plus rhEpo after VIP-E chemotherapy.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; | 1999 |
Cyclophosphamide or ifosfamide in patients with advanced and/or recurrent endometrial carcinoma: a randomized phase II study of the EORTC Gynecological Cancer Cooperative Group.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Alkylating; Cyclophosphamide; Endometrial Neopla | 1999 |
Ifosfamide given by continuous-intravenous infusion in association with vinorelbine in patients with anthracycline-resistant metastatic breast cancer: A phase I-II clinical trial.
Topics: Adenocarcinoma; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Proto | 1999 |
Phase II study of tamoxifen, ifosfamide, epirubicin and cisplatin combination chemotherapy in patients with non-small cell lung cancer failing previous chemotherapy.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pro | 2000 |
Microencapsulated cell-mediated treatment of inoperable pancreatic carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Cell Transplantation; Cytochrome P-450 CYP2B1; Dose- | 2001 |
Carcinoma of an unknown primary site: a chemotherapy strategy based on histological differentiation--results of a prospective study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cell Differe | 2001 |
[Adjuvant chemotherapy of cervix carcinoma--results of a phase II study].
Topics: Adenocarcinoma; Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin | 2001 |
Combined results from three phase II trials of neoadjuvant chemotherapy in operable adenocarcinoma of the oesophagus.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2001 |
Combination chemoimmunotherapy for extensive non-oat cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Bacterial Vaccines; Body Weight; Carcinoma, Squamous Cell; Clinical Tri | 1978 |
Evaluation of a cooperative clinical study of the cytostatic agent ifosfamide.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Breast Neoplasms; Child; Clinical Trials as Topic; Cyclopho | 1976 |
[Effect of recombinant human granulocyte colony-stimulating factor (rG-CSF) on chemotherapy-induced neutropenia in patients with lung cancer].
Topics: Adenocarcinoma; Aged; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, No | 1990 |
Continuous 5-day infusion of ifosfamide with mesna in inoperable pancreatic cancer patients: a phase II study.
Topics: Adenocarcinoma; Adult; Aged; Drug Administration Schedule; Drug Evaluation; Female; Humans; Ifosfami | 1991 |
Combination of interferons and cytostatic drugs for treatment of advanced colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; C | 1991 |
Cisplatin, etoposide, and ifosfamide in non-small cell lung carcinoma. A phase II randomized study with cisplatin and etoposide as the control arm.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Ce | 1990 |
Current role of chemotherapy in the management of ovarian cancer.
Topics: Actuarial Analysis; Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cis | 1987 |
Ifosfamide plus 5-fluorouracil for treatment of adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topi | 1987 |
95 other studies available for ifosfamide and Adenocarcinoma, Basal Cell
| Article | Year |
|---|---|
A yolk sac tumor of the pancreas and derived xenograft model effectively responded to VIP chemotherapy.
Topics: Adenocarcinoma; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cis | 2020 |
Transrectal ultrasound and magnetic resonance imaging in the evaluation of tumor size following neoadjuvant chemotherapy for locally advanced cervical cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2013 |
ERCC1 expression does not predict survival and treatment response in advanced stage non-small cell lung cancer cases treated with platinum based chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carb | 2013 |
[Efficacy of postoperative simple chemotherapy and concurrent chemoradiotherapy in FIGO stage IB2-IIB cervical cancer].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamou | 2013 |
Neoadjuvant chemotherapy followed by robotic radical hysterectomy in locally advanced cervical cancer: a multi-institution study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2014 |
Adenocarcinoma of the rete testis - a rare case of testicular malignancy.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Filgrastim; Granulocyte C | 2014 |
Oncological and pregnancy outcomes after high-dose density neoadjuvant chemotherapy and fertility-sparing surgery in cervical cancer.
Topics: Abortion, Spontaneous; Adenocarcinoma; Adolescent; Adult; Antineoplastic Combined Chemotherapy Proto | 2014 |
Impact of perioperative chemotherapy on survival in patients with advanced primary urethral cancer: results of the international collaboration on primary urethral carcinoma.
Topics: Adenocarcinoma; Aged; Albumin-Bound Paclitaxel; Antineoplastic Combined Chemotherapy Protocols; Carb | 2015 |
Neoadjuvant chemotherapy followed by large cone resection as fertility-sparing therapy in stage IB cervical cancer.
Topics: Abortion, Missed; Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin | 2015 |
Feasibility of robotic radical hysterectomy after neoadjuvant chemotherapy in women with locally advanced cervical cancer.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cis | 2016 |
Preliminary report of multimodal treatment with ifosfamide, 5-fluorouracil, etoposide and cisplatin (IFEP chemotherapy) against metastatic adenocarcinoma of the urachus.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; F | 2008 |
Neoadjuvant chemotherapy and conservative surgery for stage IB1 cervical cancer.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Che | 2008 |
"Burned out" testicular seminoma presenting as a primary gastric malignancy.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; D | 2009 |
A retrospective study of patients with locally advanced cancer of the cervix treated with neoadjuvant chemotherapy followed by radical surgery.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamou | 2009 |
Clinical evaluation of neoadjuvant chemotherapy followed by radical surgery in the management of stage IB2-IIB cervical cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, S | 2012 |
The clinical characteristic differences between thrombosis-related edema and lymphedema following radiotherapy or chemoradiotherapy for patients with cervical cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy | 2012 |
Laparoscopic lymph node dissection should be performed before fertility preserving treatment of patients with cervical cancer.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinoma, Squ | 2012 |
Surgical outcomes of robotic radical hysterectomy after neoadjuvant chemotherapy for locally advanced cervical cancer: comparison with early stage disease.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinom | 2013 |
Cancer-related thrombotic microangiopathy secondary to Von Willebrand factor-cleaving protease deficiency.
Topics: ADAM Proteins; ADAMTS13 Protein; Adenocarcinoma; Anemia, Hemolytic; Antineoplastic Combined Chemothe | 2002 |
Cure of Barrett's carcinoma by ifosfamide chemotherapy.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Alkylating; Barrett Esophagus; Esophageal Neoplasms; Fo | 2002 |
[Cellular changes in non-small cell lung cancer after neoadjuvant therapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Ce | 2004 |
[Evaluation of combined chemotherapy with vinorelbine, ifosfamide and cisplatin in the treatment of metastatic non-small cell bronchial carcinoma].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcin | 2005 |
Concomitant chemobrachyradiotherapy with ifosfamide and cisplatin followed by consolidation chemotherapy in the treatment of locally advanced adenocarcinoma or adenosquamous carcinoma of the cervix uteri.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinom | 2005 |
Another example of the highly variable clinical course of recurrent/resistant/persistent ovarian cancer.
Topics: Adenocarcinoma; Antineoplastic Agents, Alkylating; Clinical Trials, Phase II as Topic; Drug Resistan | 2006 |
[A case of primary lung adenocarcinoma accompanied by Ewing's sarcoma successfully treated with ifosfamide].
Topics: Adenocarcinoma; Antineoplastic Agents, Alkylating; Humans; Ifosfamide; Lung Neoplasms; Male; Middle | 2008 |
[Chemotherapy of the non-small cell carcinoma of the lung with ifosfamide and cisplatin].
Topics: Adenocarcinoma; Adult; Aged; Alopecia; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cisplatin; C | 1984 |
Pilot study of intravenous ifosfamide plus oral acetylcysteine in the treatment of non-small cell lung cancer.
Topics: Acetylcysteine; Adenocarcinoma; Administration, Oral; Carcinoma; Carcinoma, Small Cell; Carcinoma, S | 1981 |
Ifosfamide in the treatment of extensive non-oat cell carcinoma of the lung.
Topics: Adenocarcinoma; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cyclophosphamide; Drug Administrati | 1982 |
[Evaluation of cancer chemotherapy in primary ovarian cancer in rats--observation of histological effect by light and electron microscopy].
Topics: 9,10-Dimethyl-1,2-benzanthracene; Adenocarcinoma; Animals; Chromatin; Connective Tissue; Cyclophosph | 1984 |
Isophosphoramide mustard, a metabolite of ifosfamide with activity against murine tumours comparable to cyclophosphamide.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cell Survival; Colonic Neoplasms; Cyclophosphamide; | 1983 |
Phase I clinical study of acetylcysteine's preventing ifosfamide-induced hematuria.
Topics: Acetylcysteine; Acrolein; Adenocarcinoma; Carcinoma, Squamous Cell; Cyclophosphamide; Cystitis; Dose | 1983 |
Prophylaxis of ifosfamide toxicity with oral acetylcysteine.
Topics: Acetylcysteine; Adenocarcinoma; Aged; Carcinoma, Squamous Cell; Cyclophosphamide; Dose-Response Rela | 1983 |
N-acetylcysteine and ifosfamide in the treatment of unresectable pancreatic adenocarcinoma and refractory testicular cancer.
Topics: Acetylcysteine; Adenocarcinoma; Adult; Aged; Cyclophosphamide; Drug Evaluation; Drug Therapy, Combin | 1983 |
[Combined cytostatic chemotherapy of advanced non-small-cell bronchial carcinoma with doxorubicin and ifosfamide].
Topics: Adenocarcinoma; Adult; Aged; Carcinoma; Carcinoma, Bronchogenic; Carcinoma, Squamous Cell; Cyclophos | 1983 |
[Clinical studies of ifosfamide for gynecological malignancies].
Topics: Adenocarcinoma; Aged; Carcinoma, Squamous Cell; Cyclophosphamide; Drug Evaluation; Female; Humans; I | 1983 |
[Pulmonary metastasis of renal cell carcinoma].
Topics: Adenocarcinoma; Antineoplastic Agents; Doxorubicin; Drug Therapy, Combination; Female; Fluorouracil; | 1983 |
[Heterotransplantation of malignant human tumor of the urogenital system. Part TV. Experimental treatment using several antineoplastic agents of human renal cell tumor transplantable to nude mice].
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cyclophosphamide; Humans; Ifosfamide; Kidney Neoplas | 1982 |
Chemotherapy of malignant ovarian tumors; therapeutic results of ifosfamide.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Cyclophosphamide; Cystadenocarcinoma; Drug Administration S | 1981 |
[Cytostatic treatment of hypernephroid renal carcinoma (author's transl)].
Topics: Adenocarcinoma; Bone Neoplasms; Cyclophosphamide; Female; Humans; Ifosfamide; Kidney Neoplasms; Lung | 1980 |
Molecular and cytogenetic studies in the diagnosis of patients with poorly differentiated carcinomas of unknown primary site.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Blotting, Southern; Carcinoma | 1995 |
Metabolism of ifosfamide during a 3 day infusion.
Topics: Adenocarcinoma; Chromatography, Thin Layer; Female; Humans; Ifosfamide; Male; Neuroectodermal Tumors | 1994 |
Histopathological findings in oesophageal carcinoma with and without preoperative chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 1993 |
Lack of correlation of P-glycoprotein expression with response to MIC chemotherapy in oesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Tr | 1995 |
Intermittent continuous infusion of ifosfamide and 5-fluorouracil in patients with advanced adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; H | 1995 |
Antitumor efficacy and pharmacokinetic analysis of 4-hydroperoxycyclophosphamide in comparison with cyclophosphamide +/- hepatic enzyme effectors.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Pro | 1996 |
Mutational activation of the K-ras oncogene and the effect of chemotherapy in advanced adenocarcinoma of the lung: a prospective study.
Topics: Adenocarcinoma; Adult; Aged; Carboplatin; Carcinoma, Non-Small-Cell Lung; Etoposide; Female; Gene Ex | 1997 |
The carcinogenicity of environmental tobacco smoke.
Topics: Adenocarcinoma; Adenoma; Administration, Inhalation; Animals; Antineoplastic Agents; Biomarkers; But | 1997 |
One case of Stewart-Treves syndrome successfully treated at two years by chemotherapy and radiation therapy in a 73-year-old woman.
Topics: Adenocarcinoma; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic | 1997 |
[Efficacy of systemic chemotherapy in adenocarcinoma of the lung with pleuritis carcinomatosa].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin | 1997 |
Assessment of glucosylifosfamide mustard biodistribution in rats with prostate adenocarcinomas by means of in vivo 31P NMR and in vitro uptake experiments.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Alkylating; Drug Monitoring; Drug Screening Assays, | 1998 |
Inflammatory breast cancer: enhanced local control with hyperfractionated radiotherapy and infusional vincristine, ifosfamide and epirubicin.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality | 1998 |
[Neoadjuvant chemotherapy for advanced cervical cancer].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamou | 1999 |
Intratumoral injection of encapsulated cells producing an oxazaphosphorine activating cytochrome P450 for targeted chemotherapy.
Topics: Adenocarcinoma; Animals; Biotransformation; Capsules; Cell Line; Cell Survival; Cell Transplantation | 1998 |
Targeted chemotherapy by intratumour injection of encapsulated cells engineered to produce CYP2B1, an ifosfamide activating cytochrome P450.
Topics: Adenocarcinoma; Animals; Capsules; Cats; Combined Modality Therapy; Cytochrome P-450 CYP2B1; Genetic | 1998 |
[A case of metastatic liver tumors from prostatic cancer responding to intra-arterial infusion chemotherapy with CDDP and ifosfamide using implantable port].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasm | 1999 |
Synergistic antitumour effects of chemo-immunotherapy with an oxazaphosphorine drug and IL-2-secreting cells in a mouse colon cancer model.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Alkylating; Colonic Neoplasms; Combined Modality The | 1999 |
Combination chemotherapy in patients with malignant pleural effusions from non-small cell lung cancer : cisplatin, ifosfamide, and irinotecan with recombinant human granulocyte colony-stimulating factor support.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Tri | 2001 |
Necrotic, rather than apoptotic, cell death caused by cytochrome P450-activated ifosfamide.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Cats; Cell Line; Cells, Cultu | 2001 |
Chemotherapy inhibits skeletal muscle ubiquitin-proteasome-dependent proteolysis.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cachexia; Cisplatin; Colonic Neoplasms; Cysteine End | 2002 |
Ifosfamide in the treatment of recurrent or disseminated lung cancer: a phase II study of two dose schedules.
Topics: Adenocarcinoma; Adult; Aged; Bone Marrow; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cyclophos | 1978 |
Combined chemotherapy using cisplatin, ifosfamide and bleomycin (PIB) in the treatment of advanced and recurrent cervical carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, S | 1992 |
Phase II study of cisplatin, ifosfamide with mesna, and etoposide (PIE) chemotherapy for advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Carcin | 1992 |
[Combination chemotherapy with 254-S, ifosfamide and peplomycin for advanced or recurrent cervical cancer].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Agents; | 1992 |
Effects of chemotherapy on ultrastructure of oesophageal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cell Nucleolus; Cisplat | 1992 |
[A case of adenocarcinoma of lung cancer with multiple brain metastasis and lymphangitis carcinomatosa responding well to chemotherapy with carboplatin, etoposide and ifosfamide].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; | 1992 |
Ifosfamide and mitomycin in combination for the treatment of patients with progressive advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Sm | 1991 |
The potential for adjuvant therapy in early-stage cervical cancer.
Topics: Adenocarcinoma; Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; B | 1990 |
Pancreatoblastoma: response to chemotherapy.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Child; Child, Preschool; | 1991 |
Ifosfamide in advanced adenocarcinoma of the oesophagus or oesophageal-gastric junction area. Rotterdam Esophageal Tumor Study Group.
Topics: Adenocarcinoma; Adult; Aged; Esophageal Neoplasms; Esophagogastric Junction; Female; Humans; Ifosfam | 1991 |
[Clinical study of combination chemotherapy with cisplatin, ifosfamide, 5-FU (CIF therapy) of inoperable adenocarcinoma and large cell carcinoma of the lung].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Ce | 1991 |
Biophysical aspects of the integrated combination of cytostatic drugs with radiotherapy. Part 3: In vivo investigations on murine C3H mammary adenocarcinoma treated with cis-platinum, adriamycin, epirubicin, activated cyclophosphamide, activated isophosph
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Biophysical Phenomena; Biop | 1991 |
Ifosfamide extrapyramidal neurotoxicity.
Topics: Adenocarcinoma; Basal Ganglia Diseases; Humans; Ifosfamide; Lung Neoplasms; Lymphoma, Large B-Cell, | 1991 |
5-fluorouracil, ifosfamide and mitomycin (FIM) combination for pancreatic-biliary tumors.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bili | 1991 |
[Phase II study of ifosfamide and vindesine combination of non-small cell lung cancer in elderly patients and patients with reduced renal function].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung | 1990 |
A phase II study of ifosfamide in endometrial cancer.
Topics: Adenocarcinoma; Adult; Aged; Carcinoma, Squamous Cell; Drug Evaluation; Female; Humans; Ifosfamide; | 1990 |
[Combination chemotherapy of vincristine, ifosfamide and peplomycin in patients with advanced stage D adenocarcinoma of the prostate].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Drug Evaluation; Humans; | 1985 |
[Combination chemotherapy of vincristine, ifosfamide and peplomycin in patients with reactivated prostatic cancer].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Drug Evaluation; Hu | 1986 |
[Alternating combination chemotherapy (VIP-DMF) in patients with advanced adenocarcinoma of the prostate].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Doxorubicin; Drug A | 1987 |
[Treatment of hormonal refractory adenocarcinoma of the prostate with ifosfamide (IFM) and the combination of vincristine ifosfamide and peplomycin (VIP)].
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; | 1989 |
Ifosfamide, adriamycin and cisplatin (IAP) plus bleomycin (B) combination chemotherapy in patients with recurrent cancer of the uterine cervix.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, S | 1989 |
[Beneficial effect of cisplatin based combination chemotherapy on adenocarcinoma of the lung].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; D | 1989 |
[The course of squamous cell carcinoma antigen and CEA as prognostic criteria for response to chemotherapy in cervix cancer].
Topics: Adenocarcinoma; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumo | 1989 |
An EORTC Gastrointestinal Group phase II evaluation of epirubicin combined with ifosfamide in advanced adenocarcinoma of the pancreas. EORTC Gastrointestinal Group.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Evaluation; Epirub | 1989 |
[Combination chemotherapy with ifosfamide, 5-fluorouracil, cisplatin for stage D2 prostatic cancer].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Fluorouracil; Human | 1989 |
Etoposide, ifosfamide, and cisplatin in the treatment of advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Ce | 1987 |
[Phase II study of a three-drug combination of ifosfamide, cisplatin and vindesine in non-small-cell lung cancer].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Ce | 1988 |
[Chemotherapy of non-small cell bronchial cancer with ifosfamide in combination with cisplatin, etoposide or vindesine].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lun | 1988 |
[A case of retrocecal appendicitis occurrence during effective chemotherapy in lung cancer].
Topics: Abscess; Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Appendicitis; Bone Marrow; | 1989 |
[Treatment of non-small-cell bronchial carcinoma with cisplatin, ifosfamide, vindesine and VP 16].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Bronchogenic | 1985 |
[Chemotherapy with mitomycin C, vindesine and ifosfamide in the treatment of inoperable non-small cell bronchial carcinoma].
Topics: Adenocarcinoma; Aged; Carcinoma, Bronchogenic; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Drug | 1985 |
Experience with ifosfamide combinations (etoposide or DDP) in non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; | 1986 |
Treatment of gynecological adenocarcinomas with a combination of ifosfamide, adriamycin and cisplatin.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; | 1988 |
A phase II study of ifosfamide in advanced and relapsed carcinoma of the cervix.
Topics: Adenocarcinoma; Adult; Aged; Carcinoma, Squamous Cell; Drug Evaluation; Female; Humans; Ifosfamide; | 1986 |
[Cancer chemotherapy model using an autochthonous ovarian cancer in rats].
Topics: 9,10-Dimethyl-1,2-benzanthracene; Adenocarcinoma; Animals; Cisplatin; Female; Ifosfamide; Ovarian Ne | 1985 |
Ifosfamide: an active drug in the treatment of adenocarcinoma of the pancreas.
Topics: Acetylcysteine; Adenocarcinoma; Adult; Aged; Cyclophosphamide; Female; Humans; Ifosfamide; Male; Mid | 1985 |